Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO
· Real-Time Price · USD
6.86
-0.09 (-1.29%)
At close: Sep 04, 2025, 3:59 PM
6.86
0.00%
After-hours: Sep 04, 2025, 04:10 PM EDT
-1.29% (1D)
| Bid | 6.7 |
| Market Cap | 351.76M |
| Revenue (ttm) | 5.18M |
| Net Income (ttm) | 57.24M |
| EPS (ttm) | 0.64 |
| PE Ratio (ttm) | 10.72 |
| Forward PE | 228.33 |
| Analyst | Buy |
| Ask | 7.1 |
| Volume | 446,238 |
| Avg. Volume (20D) | 836,088 |
| Open | 6.95 |
| Previous Close | 6.95 |
| Day's Range | 6.77 - 7.00 |
| 52-Week Range | 3.93 - 7.54 |
| Beta | 1.54 |
About ABEO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABEO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABEO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Abeona Therapeutics Inc. is scheduled to release its earnings on
Nov 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+10.21%
Abeona Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
4 months ago
+23.77%
Abeona Therapeutics shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $15 to $20. Additionally, the stock may be moving on continued strength after announcing yesterday FDA for its gene therapy.
2 months ago · https://www.defenseworld.net
Squarepoint Ops LLC Buys New Position in Abeona Therapeutics Inc (NASDAQ:ABEO)Squarepoint Ops LLC bought a new position in Abeona Therapeutics Inc (NASDAQ:ABEO – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securitie...
3 months ago · seekingalpha.com
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)Abeona's ZEVASKYN approval and a $3.1 million price point are undervalued by the market, especially after a $152 million PRV sale bolstered cash reserves. Conservative launch modeling, including risk-...